Editor’s note: A recording of this event is embedded below.
The pharmaceutical industry has played a key role in battling the pandemic. But the past year has been a hard one, with biotech stocks underperforming and the Congress pushing hard to create new drug pricing legislation. Come explore what’s happening in biotech and health tech with STAT’s team of ace reporters.
- Solomon Babani, SVP, drug development & therapeutic expertise, ICON
Part 1: Alnylam’s next chapter
- Yvonne Greenstreet, MBChB, CEO, Alnylam Pharmaceuticals
- Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)
Part 2: JPM recap and look ahead
- Adam Feuerstein, senior writer, biotech, STAT
- Damian Garde, national biotech reporter, STAT
- Matthew Herper, senior writer, medicine; editorial director of events, STAT
- Megan Molteni, science writer, STAT
- Kate Sheridan, general assignment reporter, STAT
Create a display name to comment
This name will appear with your comment